MedPath

A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products

Not Applicable
Completed
Conditions
Comparative Bioavailability
Registration Number
NCT01960660
Lead Sponsor
Nordic Pharma, USA
Brief Summary

Supplementation with omega-3 fatty acids has been extensively researched and is known to provide healthful benefits for patients with a diversity of conditions and diseases. Not all omega-3 supplements are created equally however; some sources of omega-3 fatty acids are superior to others due to a greater bioavailability of omega-3 fatty acids than others, differences in source material, and processing techniques.

The purpose of this study is to determine which marketed omega-3 product provided the greatest effect, as measured against its' label claim and recommended dosage.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Participant is fluent in English
  • Participant understands the study requirements and is willing to comply with the protocol
  • Participant is willing to provide written informed consent
  • Participant is 18 years of age or older
Exclusion Criteria
  • Unwilling or unable to provide written consent
  • Participant has taken omega-3 supplements in the last 3 months
  • Participants consumes fish on a regular basis (more than 1 serving per week)
  • Females who are pregnant or breastfeeding
  • Participant has an allergy to fish or seafood
  • Participant has been diagnosed with any medical illness or conditions
  • Participant has a history of drug dependence or substance abuse (excluding nicotine)
  • Participant is taking cholesterol or triglyceride lowering medications or supplements (statins, niacin, carnitine, fibrates)
  • Individual has difficulty giving multiple blood samples

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Omega-ScoreChange from Baseline in Omega-Score at 28 days

The Omega ScoreTM is a measurement of the levels of the Omega-3 Fatty Acids in a blood sample. The summed amounts of these Omega-3 Fatty Acids (EPA+DPA+DHA) as a % of the total fatty acids represents the Omega ScoreTM in whole blood.

Secondary Outcome Measures
NameTimeMethod
Lipemic IndexTMChange from Baseline in Lipemic Index at 28 days

The Lipemic Index™ is the post-prandial rise in TG levels over a 5-hour period, following the consumption drink containing a measured amount of fat, carbohydrate and protein.

Trial Locations

Locations (1)

Nutrasource Diagnostics Inc

🇨🇦

Guelph, Ontario, Canada

Nutrasource Diagnostics Inc
🇨🇦Guelph, Ontario, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.